http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105476980-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b4711b7defc1422cdb7f86d2c95657bf |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-192 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C51-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C59-52 |
| filingDate | 2014-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff890cc70040132d8e0128d496841baf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9de4c3a8468d60a210bd79527be89695 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b3100e3fa5cbddfdf0634a700ab2dad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9492eb1471cbbc6a41dd48f041c3c9aa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8a78449654342537565e1089db26897 |
| publicationDate | 2016-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105476980-A |
| titleOfInvention | Application of biphenyl compound 4-(3', 4'-dihydroxy phenyl) cinnamic acid in drug preparation |
| abstract | The invention belongs to the field of medicine and relates to application of biphenyl compound 4-(3', 4'-dihydroxy phenyl) cinnamic acid in preparation of anti-HBV and anticomplement drug. One biphenyl compound is separated from dried root of helicteres angustifolia, experiments prove that the biphenyl compound has strong anti-HBV activity, effective concentration is low, IC50 value on HBsAg is 18.4 micrograms/ml which is significantly higher than positive control lamivudine, and suppression ratio on HBeAg is 34.5% when the maximum acellular toxicity concentration is 50 micrograms/ml; in addition, in-vitro anticomplement activity measurement results show that the biphenyl compound has strong inhibition effect on complement system canonical pathway and alternative pathway complement activation, the CH50 value on canonical pathway complement activation is 0.0022mg/ml, and the AP50 value on alternative pathway activation is 0.0057mg/ml. The compound can be further used for preparing anti-HBV drugs and anticomplement drugs. |
| priorityDate | 2014-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 104.